DESIGN THERAPEUTICS INC (DSGN) — insider trading
Health Care · NASDAQ
DESIGN THERAPEUTICS INC (DSGN) has 12 reported SEC Form 4 insider transactions in our data (latest 2026-06-09).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-06-09 | Berger Heather A. | Director | Grant / award / vesting (derivative) | 30,000 | $0.00 | $0 | Form 4 |
| 2026-06-09 | Shapiro David | Director | Grant / award / vesting (derivative) | 30,000 | $0.00 | $0 | Form 4 |
| 2026-06-09 | Gover Justin D. | Director | Grant / award / vesting (derivative) | 30,000 | $0.00 | $0 | Form 4 |
| 2026-06-09 | LAPPE RODNEY W | Director | Grant / award / vesting (derivative) | 30,000 | $0.00 | $0 | Form 4 |
| 2026-06-09 | Schmid John P. | Director | Grant / award / vesting (derivative) | 30,000 | $0.00 | $0 | Form 4 |
| 2026-06-09 | George Simeon | Director, 10% owner | Grant / award / vesting (derivative) | 30,000 | $0.00 | $0 | Form 4 |
| 2026-03-31 | Shapiro David | Director | Grant / award / vesting (derivative) | 7,500 | $0.00 | $0 | Form 4 |
| 2026-03-31 | Shapiro David | Director | Grant / award / vesting (derivative) | 60,000 | $0.00 | $0 | Form 4 |
| 2026-01-02 | Gover Justin D. | Director | Grant / award / vesting (derivative) | 45,000 | $0.00 | $0 | Form 4 |
| 2026-01-02 | Burgess Julie | Officer (Chief Accounting Officer) | Grant / award / vesting (derivative) | 150,000 | $0.00 | $0 | Form 4 |
| 2026-01-02 | Jeffries Sean | Officer (Chief Operating Officer) | Grant / award / vesting (derivative) | 375,000 | $0.00 | $0 | Form 4 |
| 2026-01-02 | Storgard Chris | Officer (Chief Medical Officer) | Grant / award / vesting (derivative) | 250,000 | $0.00 | $0 | Form 4 |
Ask the chat about DSGN's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: DESIGN THERAPEUTICS INC (DSGN).
Last updated 2026-06-09 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.